# Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

> **NCT06154447** · PHASE1 · RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 255 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-828
- **DRUG:** Placebo
- **DRUG:** Itraconazole
- **DRUG:** Midazolam
- **DRUG:** Tezacaftor
- **DRUG:** VX-118
- **DRUG:** Placebo
- **DRUG:** Deutivacaftor
- **DRUG:** VX-828

## Key facts

- **NCT ID:** NCT06154447
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-04-23
- **Final completion:** 2026-04-23
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06154447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06154447, "Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06154447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*